Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults
- [Comment] Staging prediabetes and type 2 diabetes: the time to start is now
- [Correspondence] Task shifting and task sharing in paediatric type 1 diabetes care: a global survey
- [Personal View] Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology
- [Editorial] Diabetes and cancer in the age of multimorbidity
- [Articles] Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial
- [Comment] Does continuous glucose monitoring deliver in gestational diabetes?
- [In Focus] Getting smart about the food we eat
- [Corrections] Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X
- [Correspondence] Portion sizes and caloric inequity: a hidden driver of obesity disparities
- [Articles] Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England
- [Comment] Heterogeneity in type 2 diabetes trajectories: informing public health approaches
- [Review] Adrenal tumour imaging: clinical, molecular, and radiomics perspectives
- [Articles] Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden
- [Comment] The long and winding road to precision diabetology
- [Articles] Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study
- [Comment] Cardiovascular mortality trends among people with and without diabetes
- [Correspondence] Policies on ultra-processed diets: feasible and urgent
- [Editorial] Reassessing driving safety in diabetes
- [Articles] Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial